GSK shares fell more than 6% on Friday to the bottom of Britain's blue-chip index after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier ...

Background: Global cancer statistics indicate colorectal cancer as the second leading cause of cancer-related deaths, with rectal cancer accounting for approximately 30% of cases. Despite neoadjuvant ...

Rectal cancer is one of the most common causes of cancer deaths in the western world. Individuals diagnosed with rectal cancer are mainly treated with surgery. However, the risk remains that rectal ...

A new study by a Tulane University researcher casts doubt on a widely used shortcut in rectal cancer drug trials, raising concerns that some treatments may be fast-tracked for approval without ...

A new study raises concerns about a widely used shortcut in approving rectal cancer drugs, showing that the absence of detectable tumors after treatment—known as pathologic complete response ...

Hearing problems are a common long-term side effect of some cancer treatments, especially for children and older adults. Sometimes treatment can lead to temporary or permanent hearing changes. But if ...

Thousands of women who undergo radiotherapy for low-risk breast cancer could be spared some of the side effects of treatment after a study confirmed that more targeted treatments are just as ...

Purpose: This study was to assess whether baseline magnetic resonance habitat imaging can predict the efficacy of neoadjuvant chemoradiotherapy (nCRT) in patients with locally advanced rectal cancer ...

To investigate rectal hydrogel spacer use, placement complications, and associated radiation delays in the United States.The MerativeTM MarketScan Database was used to identify prostate cancer ...